ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,505,322 | -25.4% | 120,217 | -14.3% | 0.00% | -20.0% |
| Q2 2023 | $3,358,676 | +17.9% | 140,237 | -7.4% | 0.01% | +25.0% |
| Q1 2023 | $2,849,781 | +16.5% | 151,423 | -1.4% | 0.00% | 0.0% |
| Q4 2022 | $2,445,646 | -1.4% | 153,621 | +1.3% | 0.00% | 0.0% |
| Q3 2022 | $2,481,000 | +14.1% | 151,653 | -1.7% | 0.00% | +33.3% |
| Q2 2022 | $2,174,000 | -41.6% | 154,302 | +0.3% | 0.00% | -40.0% |
| Q1 2022 | $3,725,000 | -4.3% | 153,782 | -7.8% | 0.01% | 0.0% |
| Q4 2021 | $3,894,000 | +43.6% | 166,818 | +2.2% | 0.01% | +66.7% |
| Q3 2021 | $2,712,000 | -38.2% | 163,279 | -9.3% | 0.00% | -50.0% |
| Q2 2021 | $4,389,000 | -20.2% | 179,968 | -15.6% | 0.01% | -14.3% |
| Q1 2021 | $5,500,000 | -52.0% | 213,169 | -0.5% | 0.01% | -56.2% |
| Q4 2020 | $11,457,000 | +32.3% | 214,318 | +2.1% | 0.02% | +14.3% |
| Q3 2020 | $8,659,000 | -5.1% | 209,916 | +11.5% | 0.01% | -12.5% |
| Q2 2020 | $9,126,000 | +26.3% | 188,285 | +10.1% | 0.02% | 0.0% |
| Q1 2020 | $7,228,000 | -1.7% | 171,084 | -0.5% | 0.02% | +23.1% |
| Q4 2019 | $7,355,000 | +24.5% | 171,931 | +4.7% | 0.01% | +8.3% |
| Q3 2019 | $5,909,000 | +36.3% | 164,176 | +1.2% | 0.01% | +33.3% |
| Q2 2019 | $4,336,000 | -6.9% | 162,215 | -6.4% | 0.01% | -10.0% |
| Q1 2019 | $4,656,000 | +86.9% | 173,394 | +12.6% | 0.01% | +66.7% |
| Q4 2018 | $2,491,000 | -20.3% | 154,048 | +2.3% | 0.01% | 0.0% |
| Q3 2018 | $3,126,000 | +35.9% | 150,574 | -0.0% | 0.01% | +20.0% |
| Q2 2018 | $2,300,000 | -32.0% | 150,628 | +0.0% | 0.01% | -28.6% |
| Q1 2018 | $3,384,000 | -27.9% | 150,582 | -3.4% | 0.01% | -30.0% |
| Q4 2017 | $4,693,000 | -19.9% | 155,861 | +0.2% | 0.01% | -23.1% |
| Q3 2017 | $5,858,000 | +22.0% | 155,504 | -9.7% | 0.01% | +30.0% |
| Q2 2017 | $4,801,000 | -26.5% | 172,137 | -9.4% | 0.01% | -23.1% |
| Q1 2017 | $6,534,000 | +14.1% | 190,060 | -4.3% | 0.01% | +8.3% |
| Q4 2016 | $5,729,000 | -11.7% | 198,660 | -2.6% | 0.01% | -7.7% |
| Q3 2016 | $6,491,000 | +4.6% | 204,060 | +6.7% | 0.01% | 0.0% |
| Q2 2016 | $6,208,000 | +24.0% | 191,260 | +6.8% | 0.01% | +18.2% |
| Q1 2016 | $5,005,000 | -4.9% | 179,004 | +21.2% | 0.01% | -15.4% |
| Q4 2015 | $5,265,000 | +9.5% | 147,687 | +1.6% | 0.01% | 0.0% |
| Q3 2015 | $4,807,000 | -21.1% | 145,364 | -0.1% | 0.01% | -13.3% |
| Q2 2015 | $6,096,000 | +29.5% | 145,564 | +0.8% | 0.02% | +36.4% |
| Q1 2015 | $4,707,000 | +1.2% | 144,426 | -1.4% | 0.01% | 0.0% |
| Q4 2014 | $4,652,000 | +29.1% | 146,526 | +0.7% | 0.01% | +22.2% |
| Q3 2014 | $3,603,000 | +10.9% | 145,504 | +1.1% | 0.01% | +12.5% |
| Q2 2014 | $3,250,000 | -4.9% | 143,878 | +2.4% | 0.01% | -11.1% |
| Q1 2014 | $3,418,000 | +7.8% | 140,478 | +10.7% | 0.01% | 0.0% |
| Q4 2013 | $3,171,000 | -8.4% | 126,878 | +0.7% | 0.01% | -10.0% |
| Q3 2013 | $3,461,000 | +56.2% | 125,978 | +3.2% | 0.01% | +42.9% |
| Q2 2013 | $2,216,000 | – | 122,113 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |